Indoco Remedies receives final approval from the USFDA for Allopurinol Tablets USP 200 mg

Indoco Remedies Ltd. announced the final approval of Allopurinol Tablets USP 200 mg through its Abbreviated New Drug Application (ANDA) for Allopurinol Tablets USP to market a generic equivalent to the reference listed drug (RLD), ZYLOPRIM 200 mg of Casper Pharma LLC from USFDA.

Allopurinol is used to prevent or lower high uric acid levels in the blood. It is also used to prevent or lower excess uric acid levels caused by cancer medicines or in patients with kidney stones.

This product, Allopurinol Tablets USP 200 mg, will be manufactured by Indoco Remedies Limited at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa - 403722 in India.

Commenting on the achievement, Ms. Aditi Panandikar, Managing Director said, "Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US."

Shares of Indoco Remedies Limited was last trading in BSE at Rs. 243.00 as compared to the previous close of Rs. 242.70. The total number of shares traded during the day was 18999 in over 1043 trades.

The stock hit an intraday high of Rs. 258.20 and intraday low of 233.35. The net turnover during the day was Rs. 4673798.00.

Source : Equity Bulls

Keywords

IndocoRemedies INE873D01024 Pharmaceuticals USFDA FinalApproval AllopurinolTablets